Disease relevance of Idb-106

• Antitumour activity of the silybin-phosphatidylcholine complex, IdB 1016, against human ovarian cancer [1].
• The pharmacokinetics of silybin, the main active component of silymarin, following administration of a lipophilic silybin-phosphatidylcholine complex (silipide) was evaluated in fourteen patients with cholestasis secondary to biliary extrahepatic obstruction [2].
• A pilot study on the liver protective effect of silybin-phosphatidylcholine complex (IdB1016) in chronic active hepatitis [3].

Psychiatry related information on Idb-106

• The ability of Silipide to scavenge ethanol-derived radicals along with its antioxidant activity suggests that this drug might be potentially useful in counteracting free radical-mediated injuries involved in the development of liver damage caused by alcohol abuse [4].

High impact information on Idb-106

• This study aimed to assess, in an in vivo experimental model, the growth inhibitory effects of IdB 1016 (Silipide, a complex of silybin/phosphatidylcholine) when used as a single agent against human ovarian cancer [1].
• However, such an effect is lost when pure silybin in amounts comparable to those present in Silipide is administered instead, due to the low bioavailability of uncomplexed flavonoid [4].
• We have observed that in vitro addition or in vivo pretreatment of rats with Silipide, a new 1:1 complex of silybin with phosphatidyl-choline, is able to decrease the spin trapping of hydroxyethyl radicals in microsomes from chronic alcohol-fed rats [4].
• Pharmacokinetics of silybin following oral administration of silipide in patients with extrahepatic biliary obstruction [2].

Analytical, diagnostic and therapeutic context of Idb-106

• Pharmacokinetics of silybin in bile following administration of silipide and silymarin in cholecystectomy patients [5].

References